Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) Starts Presentation at 29th Annual ROTH Conference
Catalyst Pharmaceuticals (NASDAQ: CPRX) is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), infantile spasms, and Tourette's Disorder. Firdapse® for the treatment of LEMS has received Breakthrough Therapy Designation from the FDA and orphan drug designation for LEMS, CMS and myasthenia gravis. CPP-115 has been granted U.S. orphan drug designation for the treatment of infantile spasms by the FDA and has been granted E.U. orphan medicinal product designation for the treatment of West Syndrome by the European Commission. For more information, visit the…
